Vitiligo
Conditions
Brief summary
Vitiligo is a distressing disorder of depigmentation. In spite of multiple successful therapeutic regimens, disease relapse remains a challenge to patients and physicians. Most guidelines consider systemic treatments only in rapidly progressive disease with wider surface areas. This delay in halting the immune attack, may give the chance for further disease progression as well as establishment of resident memory T cell population predisposing to future disease relapses. The aim of this study was to assess the ability of early systemic therapy of localized (\<2% BSA), recent onset (\<6 months) vitiligo to control disease activity and minimize the possibility of recurrence.
Interventions
None listed
Sponsors
Cairo University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients ≥ 6 years old of both genders * Early onset vitiligo (˂6m duration) * Body surface area (BSA) affected ≤2%
Exclusion criteria
* Patients who received any previous treatment for vitiligo * Pregnant and lactating females * Patients with other cutaneous or systemic autoimmune diseases * Patients with contraindication to systemic corticosteroids
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Duration needed to arrest of vitiligo activity | 6 months | Time needed for vitiligo patients to stop developing new lesions of vitiligo |
| Duration of maintaining vitiligo stability | 5 years | Time before any new vitiligo lesions reappear |
Outcome results
None listed